×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MRK – merck & company, inc. (new) (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MRK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/29
10:10 pm
mrk
Reed Jobs Lost His Father Steve To Cancer. Now His Cancer VC Firm Has Raised $200 Million. [Forbes]
Low
Report
Reed Jobs Lost His Father Steve To Cancer. Now His Cancer VC Firm Has Raised $200 Million. [Forbes]
1/29
12:13 pm
mrk
ISS National Lab Marks Record Year for Space-Based Scientific Results [Yahoo! Finance]
Low
Report
ISS National Lab Marks Record Year for Space-Based Scientific Results [Yahoo! Finance]
1/29
11:10 am
mrk
Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics [Yahoo! Finance]
Low
Report
Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics [Yahoo! Finance]
1/28
09:23 pm
mrk
This Stock Is Already Up 58% This Year. Is It a Buy? [Yahoo! Finance]
Low
Report
This Stock Is Already Up 58% This Year. Is It a Buy? [Yahoo! Finance]
1/28
11:31 am
mrk
What's Fueling The Rally In Merck Stock? [Forbes]
Low
Report
What's Fueling The Rally In Merck Stock? [Forbes]
1/28
10:48 am
mrk
Global Glioma Market Growth Driven by Therapeutic Innovations and Aging Population [Yahoo! Finance]
Low
Report
Global Glioma Market Growth Driven by Therapeutic Innovations and Aging Population [Yahoo! Finance]
1/27
03:07 pm
mrk
Merck Announces Second-Quarter 2026 Dividend
Low
Report
Merck Announces Second-Quarter 2026 Dividend
1/27
09:51 am
mrk
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Citigroup Inc. from $110.00 to $115.00. They now have a "neutral" rating on the stock.
Low
Report
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Citigroup Inc. from $110.00 to $115.00. They now have a "neutral" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2025
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
2.5%
merck & company, inc. (new)
7/29/2025
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
-5.0%
merck & company, inc. (new)
4/24/2025
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
0.8%
merck & company, inc. (new)
2/4/2025
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
-9.7%
merck & company, inc. (new)
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/28
04:20 pm
mrk
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Zachary Jennifer
Low
Report
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Zachary Jennifer
1/28
04:18 pm
mrk
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Williams David Michael
Low
Report
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Williams David Michael
1/28
04:17 pm
mrk
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Smart Dalton E. III
Low
Report
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Smart Dalton E. III
1/28
04:15 pm
mrk
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Romanelli Joseph
Low
Report
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Romanelli Joseph
1/28
04:12 pm
mrk
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Oosthuizen Johannes Jacobus
Low
Report
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Oosthuizen Johannes Jacobus
1/28
04:11 pm
mrk
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Litchfield Caroline
Low
Report
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Litchfield Caroline
1/28
04:09 pm
mrk
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Li Dean Y
Low
Report
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Li Dean Y
1/28
04:08 pm
mrk
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Guindo Chirfi
Low
Report
Form 4 Merck & Co., Inc. For: Jan 26 Filed by: Guindo Chirfi
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/28
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies
7.5%
3/25 Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response 6.5%
3/3 Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael 6.1%
3/2 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) 5.6%
3/17 Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough 5.3%
4/1 Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 4.2%
4/27 UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters] 3.4%
10/28 Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters] 3.3%
10/3 Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily] 2.7%
1/31 Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters] 2.3%
3/25 Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response 6.5%
3/3 Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael 6.1%
3/2 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) 5.6%
3/17 Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough 5.3%
4/1 Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 4.2%
4/27 UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters] 3.4%
10/28 Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters] 3.3%
10/3 Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily] 2.7%
1/31 Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters] 2.3%
TOP News Decliners
3/13
Trump's Coronavirus Fiscal Boost, Test Push Fuels Dow Jones Bounce [Investor's Business Daily]
-8.6%
3/20 Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer -7.0%
2/5 Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results -5.2%
4/7 Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type -4.5%
9/9 Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress -4.2%
4/21 Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts -4.2%
4/28 Q1/2020 3/31/2020 EPS 1.500 ZacksConsensus 1.390 ActVsEst 0.110 - Beat -3.8%
7/30 Form 8-K Merck & Co., Inc. For: Jul 30 -3.7%
3/6 Volatility And Pullback Presenting An Opportunity With Merck [Seeking Alpha] -3.6%
8/14 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer -3.1%
3/20 Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer -7.0%
2/5 Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results -5.2%
4/7 Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type -4.5%
9/9 Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress -4.2%
4/21 Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts -4.2%
4/28 Q1/2020 3/31/2020 EPS 1.500 ZacksConsensus 1.390 ActVsEst 0.110 - Beat -3.8%
7/30 Form 8-K Merck & Co., Inc. For: Jul 30 -3.7%
3/6 Volatility And Pullback Presenting An Opportunity With Merck [Seeking Alpha] -3.6%
8/14 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: